Immatics N.V. NASDAQ:IMTX

Immatics N.V. stock price today

$5.7
-1.42
-20.06%
Financial Health
0
1
2
3
4
5
6
7
8
9

Immatics N.V. stock price monthly change

-43.86%
month

Immatics N.V. stock price quarterly change

-43.86%
quarter

Immatics N.V. stock price yearly change

-34.53%
year

Immatics N.V. key metrics

Market Cap
828.33M
Enterprise value
242.54M
P/E
11
EV/Sales
1.60
EV/EBITDA
5.62
Price/Sales
2.27
Price/Book
3.04
PEG ratio
0.15
EPS
-0.98
Revenue
74.64M
EBITDA
-68.81M
Income
-80.31M
Revenue Q/Q
210.81%
Revenue Y/Y
-6.36%
Profit margin
22.5%
Oper. margin
9.18%
Gross margin
0%
EBIT margin
9.18%
EBITDA margin
-92.18%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Immatics N.V. stock price history

Immatics N.V. stock forecast

Immatics N.V. financial statements

Immatics N.V. (NASDAQ:IMTX): Profit margin
Jun 2023 22.35M -24.61M -110.09%
Sep 2023 5.92M -26.48M -447%
Dec 2023 15.92M -26.14M -164.24%
Mar 2024 30.44M -3.07M -10.09%
Immatics N.V. (NASDAQ:IMTX): Analyst Estimates
2025 53.21M -119.88M -225.3%
2026 45.22M -150.01M -331.72%
2027 62.80M -93.26M -148.51%
2028 111.35M -81.66M -73.33%
  • Analysts Price target

  • Financials & Ratios estimates

Immatics N.V. (NASDAQ:IMTX): Debt to assets
Jun 2023 410189000 191.97M 46.8%
Sep 2023 437450000 189.69M 43.36%
Dec 2023 509965000 284.88M 55.86%
Mar 2024 653730305 252.57M 38.64%
Immatics N.V. (NASDAQ:IMTX): Cash Flow
Jun 2023 -6.60M -16.83M 36.45M
Sep 2023 -30.52M -70.57M 49.90M
Dec 2023 79.07M 59.73M -972K
Mar 2024 -32.79M -243.24M 175.67M

Immatics N.V. alternative data

Immatics N.V. (NASDAQ:IMTX): Employee count
Aug 2023 402
Sep 2023 402
Oct 2023 210
Nov 2023 210
Dec 2023 433
Jan 2024 433
Feb 2024 433
Mar 2024 432
Apr 2024 432
May 2024 432
Jun 2024 432
Jul 2024 432

Immatics N.V. other data

15.89% -36.56%
of IMTX is owned by hedge funds
10.93M -23.11M
shares is hold by hedge funds
Monday, 18 November 2024
zacks.com
zacks.com
globenewswire.com
Friday, 8 November 2024
globenewswire.com
Tuesday, 5 November 2024
zacks.com
Friday, 11 October 2024
seekingalpha.com
Thursday, 10 October 2024
globenewswire.com
benzinga.com
globenewswire.com
globenewswire.com
Friday, 4 October 2024
globenewswire.com
Monday, 16 September 2024
globenewswire.com
Friday, 6 September 2024
globenewswire.com
Tuesday, 13 August 2024
zacks.com
globenewswire.com
Monday, 22 July 2024
zacks.com
zacks.com
Tuesday, 14 May 2024
Zacks Investment Research
Saturday, 27 April 2024
Seeking Alpha
Monday, 6 November 2023
Zacks Investment Research
Thursday, 12 October 2023
Zacks Investment Research
Monday, 9 October 2023
Seeking Alpha
Monday, 11 September 2023
Proactive Investors
Reuters
Thursday, 17 August 2023
Zacks Investment Research
Monday, 19 June 2023
Zacks Investment Research
Wednesday, 3 May 2023
Zacks Investment Research
Monday, 16 January 2023
Seeking Alpha
Thursday, 17 November 2022
Zacks Investment Research
Tuesday, 11 October 2022
Zacks Investment Research
  • What's the price of Immatics N.V. stock today?

    One share of Immatics N.V. stock can currently be purchased for approximately $5.7.

  • When is Immatics N.V.'s next earnings date?

    Unfortunately, Immatics N.V.'s (IMTX) next earnings date is currently unknown.

  • Does Immatics N.V. pay dividends?

    No, Immatics N.V. does not pay dividends.

  • How much money does Immatics N.V. make?

    Immatics N.V. has a market capitalization of 828.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 68.76% to 54M US dollars.

  • What is Immatics N.V.'s stock symbol?

    Immatics N.V. is traded on the NASDAQ under the ticker symbol "IMTX".

  • What is Immatics N.V.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Immatics N.V.?

    Shares of Immatics N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Immatics N.V. have?

    As Jul 2024, Immatics N.V. employs 432 workers.

  • When Immatics N.V. went public?

    Immatics N.V. is publicly traded company for more then 6 years since IPO on 12 Dec 2018.

  • What is Immatics N.V.'s official website?

    The official website for Immatics N.V. is immatics.com.

  • How can i contact Immatics N.V.?

    Immatics N.V. can be reached via phone at +49 7071 53970.

Immatics N.V. company profile:

Immatics N.V.

immatics.com
Exchange:

NASDAQ

Full time employees:

542

Industry:

Biotechnology

Sector:

Healthcare

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Paul-Ehrlich-Strasse 15
Tübingen, 72076

CIK: 0001809196
ISIN: NL0015285941
CUSIP: N44445109